Selleck Chemicals - Model A2053 -Monalizumab (Anti-Human CD159a)

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.